贺普丁联合抗乙肝特异性转移因子治疗慢性乙肝临床研究

目的　探讨贺普丁联合抗乙肝特异性转移因子治疗慢性乙型肝炎的临床疗效及安全性。方法　对照组常规保肝治疗的基础上 ,贺普丁 10 0 mg,每日 1次 ,连用 1年。治疗组在对照组的基础上加用抗乙肝特异性转移因子注射剂 2 mg,肌注 ,每日 1次 ,连用 3个月 ,停 3个月后继续用 3个月。治疗后 3、6、12个月时查血清肝功能、HBe Ag、HBVDNA和 CD4+ / CD8+ 。结果　对照组 /治疗组 HBe Ag阴转率 10 .5 2 %～ 42 .11% / 2 7.18%～ 6 6 .6 7% ;HBVDNA阴转率84.2 1%～ 73.6 8% / 86 .11%～ 94.44 % ;AL T复常率 6 5 .79%～ 71.0 5 % / 77.78%～ 88.89% ;CD4+ / CD8+ 1.17± 0 .10 /1.45± 0 .2 9。各项指标随时间推移明显改善。结论　贺普丁对 HBV有明显的抑制作用 ,联合抗乙肝特异性转移因子治疗 ,特异性提高机体免疫功能 ,能明显提高疗效、费用适宜 ,安全有效

The Preliminary Study of Combination Therapy with Lamivudine and Spectcific Transfer Factor for Hepatilis B Virus

Objective:To study whether combination therapy with Lamivudine (LAM) and spectiffic transfer factor for hepatitis B virus(STF-HB) was the effect and safety for treatment of chronic hepatitis B. Methods :The chronic hepatitis treated with either LAM (n = 38. 100mg. daily for 52 weeks) or LAM plus STF-HB (n = 36.100mg. LAM daily plus 2mg STF-HB daily for 12 weeks,stopping 12 weeks, continue using 12 weeks). The end of treatment response were evaluated based on the serum liverfunctional or thymphocyte and seronegative of HBeAg. or PCRHBVDNA. Results: In combined treatment group and alone LAM group, there is a significantly statistical difference between the combined treatment group and the alone LAM group. 36～52 weeks later ALT normalization rate for two groups were 77.18%～88.89% and 65.79%～71.05% . 52 weeks later CD4+/CD8+ two groups were 1.45+0. 29 and 1. 17±0. 10. The serocoversion rate for HBeAg and HBVDNA were 27.78%～66.67%/10. 52% ～42.11% and 86. 11% ～94.44%/84. 21%～89. 47%. in 12～52 weeks. Conclusion: Combination therapy of LAM and STF-HB has higher efficacy than LAM alone the treatment of the patients with chronic hepatitis B.